TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00519298
Drug: SAM-531
Normalized name: SAM
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosage form : 0.5 mg and 5 mg capsules 3 different single doses : 1 mg, 3mg and 10 mg of SAM-531
Study: NCT00519298
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dosage form: 5 mg encapsulated tablets one single dose of 5 mg.
Study: NCT00413166
Drug: All-Trans Retinoic Acid (ATRA)
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction: 45 mg/m2 daily by mouth in 2 divided doses beginning day 1
Study: NCT00413166
Drug: Arsenic Trioxide (ATO)
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Induction: 0.15 mg/kg daily IV beginning day 1
Study: NCT00413166
Drug: Idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. 12 mg/m2 one dose only (may be given on day 1 to 5 of induction)~2. If either ATRA or ATO are discontinued due to toxicity, idarubicin 12 mg/m2 x 2 doses will be administered once every 4 to 5 weeks (depending on the recovery of counts) until 28 weeks has elapsed from the Complete Recovery date.
Study: NCT00413166
Drug: Gemtuzumab Ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Induction: 9 mg/m2 on day 1 of induction
Study: NCT01606137
Drug: GW-1000-02
Normalized name: GW-559090
DrugBank: GW-559090 (DB06508)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contained delta-9-tetrahydrocannabinol (THC) (27 mg/ml) and cannabidiol (CBD) (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each 100 μl actuation of the pump action spray delivered 2.7 mg THC and 2.5 mg CBD. A maximum daily exposure of 130 mg THC was specified by the UK regulatory authority authorisation.
Study: NCT00135070
Drug: Detemir
Normalized name: Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02061800
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard of care: Each dose of alemtuzumab is to be diluted in D5W or NS (maximum concentration: 0.3 mg/mL) for IV infusion over two hours.
Study: NCT02320318
Drug: Ibodutant 10 mg
Normalized name: Ibodutant
DrugBank: Ibodutant (DB12042)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet, once daily.
Study: NCT00528437
Drug: temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 13-cis-retinoic acid, when absorbed, may be subject to first-pass metabolism and subsequent plasma (and tumor) concentrations will depend on the rate of metabolism to the inactive 4-oxo metabolite.
Study: NCT00560183
Drug: Q8003 (morphine sulfate and oxycodone hydrochloride)
Normalized name: Morphine Sulfate and Naltrexone Hydrochloride Extended-Release Capsules
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules, four different mg dosage strengths
Study: NCT02094937
Drug: Fluticasone Furoate/Vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: FF/VI 100mg/25 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler
Study: NCT02094937
Drug: Fluticasone Furoate 100 mcg
Normalized name: fluticasone furoate 100 mcg/inh inhalation powder
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: FF 100 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler
Study: NCT02094937
Drug: Fluticasone Propionate 250 mcg
Normalized name: fluticasone propionate 250 MCG/ACTUAT Dry Powder Inhaler
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: FP 250 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler
Study: NCT02094937
Drug: Fluticasone Propionate 100 mcg
Normalized name: fluticasone propionate 100 MCG/ACTUAT Dry Powder Inhaler
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: FP 100 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler
Study: NCT02094937
Drug: Fluticasone Furoate Placebo
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Matching placebo of Fluticasone Furoate will be given once daily in the evening via dry powder inhaler
Study: NCT02094937
Drug: Fluticasone Propionate Placebo
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Matching placebo of Fluticasone Propionate will be given twice daily (morning and evening) via dry powder inhaler
Study: NCT01237964
Drug: Xiaflex (FDA approved collagenase)
Normalized name: Xiaflex
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.58mg of collagenase will be diluted in saline and injected in 3 points surrounding the limiting contracture
Study: NCT01213550
Drug: Chlorhexidine gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01962415
Drug: Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT01962415
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous (IV) administration.
Study: NCT01962415
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration
Study: NCT01962415
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV administration
Study: NCT01962415
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV administration
Study: NCT04263454
Drug: Endotoxin, Escherichia Coli
DrugBank: Escherichia coli (DB16539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endotoxin is a purified lipopolysaccharide prepared from E. coli O:113 and vialed under good manufacturing practice guidelines.
Study: NCT01016561
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04611971
Drug: Benlysta
Normalized name: Benlysta
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Benlysta injection will be administered subcutaneously.
Study: NCT04611971
Drug: Candin
Normalized name: Candin
DrugBank: Candida albicans (DB10429)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candin will be administered intradermally along with NaCl solution.
Study: NCT01402583
Drug: PEG IFN/Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PEG IFN/Ribavirin
Study: NCT04589026
Drug: Cosentyx
Normalized name: Cosentyx
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cosentyx injection will be administered subcutaneously.
Study: NCT04589026
Drug: Candin
Normalized name: Candin
DrugBank: Candida albicans (DB10429)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candin will be administered interadermally along with NaCl solution.
Study: NCT01789294
Drug: Mesalamine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A standard 50 mg/kg/die daily dose of oral mesalamine was prescribed by Pediatric Gastroenterologists, which informed parents of potential side effects. Whether the drug was not well tolerated, patients were drop out. Treatment was discontinued at time 1 to look for symptom recurrence.
Study: NCT04484012
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04471597
Drug: Bupivacaine Hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 ml of bupivacaine 0.5% will be installed topically around the ETT using ordinary syringe before the expected end of the surgery, this will be followed by manual ventilation using about the double tidal volume for 6-8 times or more to get air bubbles distributed within the upper airway to anesthetize the oropharynx and spread around ETT to the adjacent mucosal structures (laryngopharynx, larynx, and upper part of the trachea) then the cuff will be inflated to the previous pressure and patient will be mechanically ventilated as usual.
Study: NCT01473056
Drug: JTK-853
Normalized name: JTK-853
DrugBank: JTK-853 (DB13095)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, twice a day for 3 days
Study: NCT00634283
Drug: venlafaxine
Normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: venlafaxine IR 150mg
Study: NCT01880099
Drug: Galantamine 8mg
Normalized name: galantamine 8 MG
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8mg of galantamine compared to placebo
Study: NCT01880099
Drug: Galantamine 16mg
Normalized name: galantamine hydrobromide 16 MG
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16mg of galantamine compared to placebo
Study: NCT03083132
Drug: modafinil 50mg
Normalized name: ARMODAFINIL 50MG TAB
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 capsule oral daily
Study: NCT01473056
Drug: Dose 2 JTK-853
Normalized name: JTK-853
DrugBank: JTK-853 (DB13095)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, twice a day for 3 days
Study: NCT01473056
Drug: Dose 3 JTK-853
Normalized name: JTK-853
DrugBank: JTK-853 (DB13095)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, three times a day for 3 days
Study: NCT01473056
Drug: Dose 4 JTK-853
Normalized name: JTK-853
DrugBank: JTK-853 (DB13095)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, twice a day for 3 days
Study: NCT01035320
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After a placebo only run-in period patients (two groups) are treated with simvastatin + ezetimibe and simvastatin + placebo in a cross-over trial. Ezetimibe effects on top of simvastatin will be evaluated as the primary aim; simvastatin effects compared to run-in on placebo will be evaluated as a secondary aim.
Study: NCT02061800
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of care: Tacrolimus dosing will be 0.03mg/kg/24 hours as continuous IV infusion or 0.12 mg/kg/day po divided Q8-12 hr
Study: NCT02061800
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of care: Melphalan 45mg/m2 (1.5 mg/kg IV for children \<1 year of age or \<10 kg) diluted in 0.9% NS to a concentration of 0.1- 0.45mg/ml, given IV over 30 minutes.
Study: NCT03687021
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Different routes of administration of progesterone; Whether there is endometriosis
Study: NCT00563303
Drug: NaCl
Normalized name: NaCl
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 48mL from Day 1 to Day 6
Study: NCT04425824
Drug: Toripalimab combine with Rituximab
Normalized name: Toripalimab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Toripalimab is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2).~Drug: Rituximab Rituximab is an antibody to CD20 molecules. One of the mechanisms of killing tumor cells is through antibody-dependent cell-mediated cytotoxicity (ADCC).
Study: NCT04672330
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) before surgery（radical nephroureterectomy, segmental ureteral resection, endoscopic ablation）
Study: NCT06478355
Drug: Chemotherapy drug
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TP:albumin-bound paclitaxel 110-130mg/m2,d1,d8;cis-platinum 60-75mg/m2,d1 Q3W
Study: NCT01092143
Drug: BI 671800
Normalized name: BI-671800
DrugBank: BI-671800 (DB12524)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 671800
Study: NCT01092143
Drug: Fluticasone propionate placebo
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo matching Fluticasone propionate
Study: NCT01092143
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate
Study: NCT01092143
Drug: BI 671800 Placebo
Normalized name: BI-671800
DrugBank: BI-671800 (DB12524)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 671800
Study: NCT02407470
Drug: Rabbit antithymoglobulin (ATG)
Normalized name: Rabbit ATG
DrugBank: Rabbit (DB10415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabbit ATG at 3.5 mg/kg/dose IV is given from day -6 to -2.
Study: NCT03163784
Drug: Antibiotic
Normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic pre-treatment
Study: NCT01226043
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Pharmaceutical form: solution for injection~* Route of administration: subcutaneous
Study: NCT00092690
Drug: Comparator: atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01520454
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV saline at 0.83 mL/kg/hr for six hours
Study: NCT01520454
Drug: Intralipid
Normalized name: Intralipid
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
Study: NCT02185846
Drug: DYNABAC 250 MG ENTERIC COATED TABLET
Normalized name: dirithromycin
DrugBank: Dirithromycin (DB00954)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02185846
Drug: DIRITHROMYCIN 500 MG ENTERIC COATED TABLET
Normalized name: dirithromycin
DrugBank: Dirithromycin (DB00954)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01805271
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: (5 or 10 mg/day, i.e. 1 or 2 tablets/day)
Study: NCT02542150
Drug: acetate
Normalized name: Acetate
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetate infusion, saline infusion, functional magnetic resonance imaging (fMRI) scan
Study: NCT02542150
Drug: alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a jello shot containing alcohol, a jello shot containing no alcohol, fMRI scan.
Study: NCT01122472
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily for 3 weeks every 4 weeks for 24 months
Study: NCT02466373
Drug: Clonidine (Catapresan®) 0,150 mg/ml, ampoule 1 ml
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clonidine intravenous
Study: NCT02061800
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard of care: Busulfan will be given IV in 0.9% sodium chloride or D5W to a final solution for infusion equal to 10 times the volume of diluent to Busulfex (to a concentration \>0.5 mg/mL), through a central venous access device over 2 hours.
Study: NCT03813771
Drug: Benepali
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Benepali will be adminstered subcutaneously at a dose of 50mg weekly and discontinued at the primary endpoint (24 weeks).
Study: NCT03813771
Drug: Sulfasalazine
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfasalazine will be added at follow up visits (T2T care) if the subject fails to achieve low disease activity,administered orally at a dose of 1g twice daily.
Study: NCT03813771
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine will be added at follow up visits (T2T care) if the subject fails to achieve low diseaseactivity, administered at a dose of 200mg daily.
Study: NCT02993159
Drug: Afimoxifene
Normalized name: Afimoxifene
DrugBank: Afimoxifene (DB04468)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied to the breast
Study: NCT02993159
Drug: Tamoxifen Citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01324063
Drug: amsacrine
Normalized name: amsacrine
DrugBank: Amsacrine (DB00276)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01720212
Drug: YM178
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT01464944
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Paracetamol, and 2 Placebo tablets of Acetylsalicylic Acid
Study: NCT01464944
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Acetylsalicylic Acid
Study: NCT01324063
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01324063
Drug: daunorubicin hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03672318
Drug: CAR138 T Cells
Normalized name: tisagenlecleucel
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The MTD is defined as the dose at which approximately 0.20 of subjects experience DLT dose escalation guided by the continual reassessment method (CRM).~Six dose levels will be evaluated:~Dose level 1: 5X10\^6 cells/m\^2 Dose level 2: 1X10\^7 cells/m\^2 Dose level 3: 2.5X10\^7 cells/m\^2 Dose level 4: 5X10\^7 cells/m\^2 Dose level 5: 1x10\^8 cells/m\^2 Dose level 6: 2x10\^8 cells/m\^2~Six subjects will be enrolled at the MTD to better characterize safety at that dose level.~Cell Administration: CAR138 T cells will be given by intravenous injection over through either a peripheral or a central line.~The lymphodepletion regimen will consist of intravenous cyclophosphamide 300 mg/m\^2 and fludarabine 30 mg/m\^2 given once daily for three days.
Study: NCT00650234
Drug: Metformin Hydrochloride ER Tablets 500 mg
Normalized name: metformin hydrochloride Extended Release Oral Tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500mg, single dose fasting
Study: NCT02061800
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care: Fludarabine will be given IV in 50-100 ml of D5W or 0.9% sodium chloride, over 30 minutes.
Study: NCT06135675
Drug: TNP-2092 capsules
Normalized name: TNP-2092
DrugBank: TNP-2092 (DB16312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration orally.
Study: NCT03555890
Drug: Levocetirizine IRT 5 mg
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levocetirizine IRT will be available as film-coated tablets. Subjects will receive a single dose of 5 mg levocetirizine IRT. Subjects will receive levocetirizine IRT with 150 mL water in both Part (1 and 2).
Study: NCT01278160
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered subcutaneously (under the skin), twice daily with a dosage of 2/3 and 1/3 total daily dose before breakfast and before dinner, in combination with metformin.
Study: NCT01278160
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered subcutaneously (under the skin), twice daily with a split dosage of 1/2 and 1/2 total daily dose before breakfast and before dinner, in combination with metformin.
Study: NCT04024761
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine is a chemotherapy agent
Study: NCT04096170
Drug: IV lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients randomized to the IV lidocaine group will receive a 100 mg lidocaine bolus on induction then an infusion of 1.5 mg/kg/hr prior to incision. This infusion will continue throughout operation and into the PACU for 1 hour OR until the 2gm/250 mL D5W bag has been infused, whichever occurs first.
Study: NCT02061800
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of care: Methylprednisolone will be give IV slow infusion over 15-30 minutes.
Study: NCT00077051
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00077051
Drug: cytochlor
Normalized name: Cytochlor
DrugBank: Cytochlor (DB12383)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00077051
Drug: tetrahydrouridine
Normalized name: Tetrahydrouridine
DrugBank: Tetrahydrouridine (DB12484)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01278160
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets 500 mg administered orally with meals. Pre-trial dose and regimen unchanged
Study: NCT02378623
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo. The randomization will be performed by a computer generated block randomization protocol. Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (\<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.